Cassava appoints Dawn Bir to board; plans simufilam TSC-epilepsy study in H1 2026

FILANA THERAPEUTICS, INC.

Dawn Bir appointed as Class I director effective Oct 21, 2025; board expanded to eight members.
Bir is a seasoned biopharma executive with prior roles at Reata, Geron, Soleno, and Pharmacyclics.
Company plans to initiate first clinical study for simufilam in TSC-related epilepsy in first half of 2026.
Bir eligible for standard non-employee director compensation; no material interests or arrangements disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.